In Vivo Quantitative Imaging of Glioma Heterogeneity Employing Positron Emission Tomography.

Abstract

Glioblastoma is the most common primary brain tumor, highly aggressive by being proliferative, neovascularized and invasive, heavily infiltrated by immunosuppressive glioma-associated myeloid cells (GAMs), including glioma-associated microglia/macrophages (GAMM) and myeloid-derived suppressor cells (MDSCs). Quantifying GAMs by molecular imaging could support patient selection for GAMs-targeting immunotherapy, drug target engagement and further assessment of clinical response. Magnetic resonance imaging (MRI) and amino acid positron emission tomography (PET) are clinically established imaging methods informing on tumor size, localization and secondary phenomena but remain quite limited in defining tumor heterogeneity, a key feature of glioma resistance mechanisms. The combination of different imaging modalities improved the in vivo characterization of the tumor mass by defining functionally distinct tissues probably linked to tumor regression, progression and infiltration. In-depth image validation on tracer specificity, biological function and quantification is critical for clinical decision making. The current review provides a comprehensive overview of the relevant experimental and clinical data concerning the spatiotemporal relationship between tumor cells and GAMs using PET imaging, with a special interest in the combination of amino acid and translocator protein (TSPO) PET imaging to define heterogeneity and as therapy readouts.

• Authors: Cristina Barca, Claudia Foray, Bastian Zinnhardt, Alexandra Winkeler, Ulrich Herrlinger, Oliver M Grauer, Andreas H Jacobs
• Journal: Cancers (Cancers (Basel)) Vol. 14 Issue 13 (Jun 27 2022) ISSN: 2072-6694 [Print] Switzerland
• PMID: 35804911 (Publication Type: Journal Article, Review)